This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vuorio, A. F. Articles by Kontula, K. Search for Related Content PubMed PubMed Citation Articles by Vuorio, A. F. Articles by Kontula, K.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3332-3337.)
© 1997 American Heart Association, Inc.

Articles

Neonatal Diagnosis of Familial Hypercholesterolemia in Newborns Born to a Parent With a Molecularly Defined Heterozygous Familial Hypercholesterolemia

Alpo F. Vuorio; Hannu Turtola; ; Kimmo Kontula

From Department of Medicine (A.F.V, K.K.), University of Helsinki, FIN-00290 Helsinki, Finland and Central Hospital of North Karelia (H.T.), FIN-80210 Joensuu, Finland.

Correspondence to Professor Kimmo Kontula, MD, Department of Medicine, University of Helsinki, FIN-00290 Helsinki, Finland.

Abstract This study was designed to compare blood lipid levels in newborn individuals with molecularly defined heterozygous familial hypercholesterolemia [FH] to those in nonaffected babies and to clarify the value of lipid determinations in assessment of diagnosis of FH at birth and 1 year of age. Twenty-five babies were born to 21 parents with DNA-documented heterozygous FH. Analysis of their cord blood samples revealed 11 newborns with the FH-North Karelia [FH-NK] mutation, 3 newborns with the FH-Helsinki [FH-HKI] mutation, and 11 nonaffected newborns. Cord serum total [TC] and LDL cholesterol [LDL-C] levels (mean±SD) in affected newborns (2.60±0.70 and 1.77±0.56, respectively) were significantly (P<.001) higher than those in nonaffected ones (1.54±0.23 and 0.78±0.15, respectively) and another cohort of 30 randomly selected control samples from apparently healthy newborns (1.84±0.46 and 1.03±0.30, respectively). However, there was overlapping of individual lipid levels in these three groups precluding the use of TC or LDL-C determinations in neonatal diagnosis of FH. In contrast, 1 year follow-up samples from 10 affected and 7 nonaffected individuals, as well as additional samples collected from another group of 8 affected and 9 nonaffected individuals, indicated that serum cholesterol levels showed much greater increment in children with FH. Thus, at the age of 1 year the mean serum TC and LDL-C levels in the affected infants (8.38±1.18 and 7.02±1.07, respectively) were much higher (P<.001) than the corresponding levels (4.40±0.66 and 2.89±0.68, respectively) in the nonaffected infants, and the individual ranges of TC and LDL-C levels were nonoverlapping in these two groups. Serum HDL cholesterol [HDL-C] levels in 1-year-old children with FH (0.95±0.14) were approximately 20% lower than those of their nonaffected counterparts (1.16±0.15, P<.001), after being similar at birth. In conclusion, phenotypic expression of heterozygous FH, as defined by molecular analysis of genomic DNA, is evident in serum LDL-C (but not HDL-C) levels already at birth, but for diagnostic purposes blood lipid determinations carried out at the age of 1 year are highly superior to those performed at birth.

Key Words: receptors, low-density lipoprotein • mutation • polymerase chain reaction • cord blood • North Karelia

This article has been cited by other articles:

				H. Nagasaka, T. Miida, K. Hirano, A. Ota, T. Yorifuji, T. Takatani, H. Tsukahara, M. Takayanagi, S.-P. Hui, K. Kobayashi, et al. Reduced Apolipoprotein E-Rich High-Density Lipoprotein Level at Birth Is Restored to the Normal Range in Patients with Familial Hypercholesterolemia in the First Year of Life J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 779 - 783. [Abstract] [Full Text] [PDF]

				M. Hedman, T. Matikainen, A. Fohr, M. Lappi, S. Piippo, M. Nuutinen, and M. Antikainen Efficacy and Safety of Pravastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia: A Prospective Clinical Follow-Up Study J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1942 - 1952. [Abstract] [Full Text] [PDF]

				A. F. Vuorio, H. Gylling, H. Turtola, K. Kontula, P. Ketonen, and T. A. Miettinen Stanol Ester Margarine Alone and With Simvastatin Lowers Serum Cholesterol in Families With Familial Hypercholesterolemia Caused by the FH-North Karelia Mutation Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 500 - 506. [Abstract] [Full Text] [PDF]

				H. Schuster and F. C. Luft Clinical Criteria Versus DNA Diagnosis in Heterozygous Familial Hypercholesterolemia : Is Molecular Diagnosis Superior to Clinical Diagnosis? Arterioscler Thromb Vasc Biol, March 1, 1998; 18(3): 331 - 332. [Full Text] [PDF]